<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER
        </div>
        <div class="card-body">
                <p>Dysregulation of pleiotropic growth factors, receptors and their downstream signaling pathway components represent a central protumorigenic principle in human hepatocarcinogenesis. Especially the Insulin-like Growth Factor/IGF-1 receptor (IGF/IGF-1R), Hepatocyte Growth Factor (HGF/MET), Wingless (Wnt/beta-catenin/FZD), Transforming Growth Factor alpha/Epidermal Growth Factor receptor (TGFalpha/EGFR) and Transforming Growth Factor beta (TGFbeta/TbetaR) pathways contribute to proliferation, antiapoptosis and invasive behavior of tumor cells. This review focuses on the relevant alterations in these pathways identified in human human hepatocellular carcinomas (HCCs). Resultant functional effects are modulated by multiple cross-talks between the different signaling pathways and additional tumor-relevant factors, such as cyclooxygenase-2 and p53. Several specific strategies are currently under development such as receptor kinase inhibitors, neutralizing antibodies and antagonistic proteins, which may improve the systemic treatment of human HCCs.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M18219">M18219</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:7046">ncbigene:7046</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7040">ncbigene:7040</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7039">ncbigene:7039</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8324">ncbigene:8324</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:51339">ncbigene:51339</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8313">ncbigene:8313</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:4233">ncbigene:4233</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:8312">ncbigene:8312</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5300">ncbigene:5300</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1499">ncbigene:1499</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:7048">ncbigene:7048</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2064">ncbigene:2064</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1956">ncbigene:1956</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3082">ncbigene:3082</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3481">ncbigene:3481</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M18219&#39;, name=&#39;BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER&#39;), definition=&#39;Dysregulation of pleiotropic growth factors, receptors and their downstream signaling pathway components represent a central protumorigenic principle in human hepatocarcinogenesis. Especially the Insulin-like Growth Factor/IGF-1 receptor (IGF/IGF-1R), Hepatocyte Growth Factor (HGF/MET), Wingless (Wnt/beta-catenin/FZD), Transforming Growth Factor alpha/Epidermal Growth Factor receptor (TGFalpha/EGFR) and Transforming Growth Factor beta (TGFbeta/TbetaR) pathways contribute to proliferation, antiapoptosis and invasive behavior of tumor cells. This review focuses on the relevant alterations in these pathways identified in human human hepatocellular carcinomas (HCCs). Resultant functional effects are modulated by multiple cross-talks between the different signaling pathways and additional tumor-relevant factors, such as cyclooxygenase-2 and p53. Several specific strategies are currently under development such as receptor kinase inhibitors, neutralizing antibodies and antagonistic proteins, which may improve the systemic treatment of human HCCs.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;16799620&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7046&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7040&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7039&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8324&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;51339&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8313&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;4233&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;8312&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5300&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1499&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7048&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2064&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1956&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3082&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3481&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Arthur Liberzon&#39;], &#39;exact_source&#39;: [&#39;Table 1&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>